P-1309 - Acetylcholinesterase inhibitors for schizophrenia

Abstract

The Acetylcholinesterase inhibitors (Donepezil, Rivastigmine and Galantamine) have been studied in the cognitive deficit states like Alzheimer’s and others and have been in use for sometime. These new group of compounds are being tried in the treatment of schizophrenia; there are no existing systematic reviews of these groups of compounds.We included all clinical randomised trials comparing acetylcholinesterase inhibitors with antipsychotics or placebo either alone or in combination for schizophrenia. The outcomes were grouped into the short term (up to 12 weeks), medium term (13–26 weeks) and long term (over 26 weeks). The Primary outcome was improvement in global state.We were able to incl..